Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Safety - Adverse Events in participants
研究概览
简要总结
To determine the safety of administering anakinra plus the physician's chemotherapy choice (TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with metastatic breast cancer (MBC), as well as determining blood immune cell transcriptional signatures in patients who undergo IL-1 receptor blockade.
详细描述
In an attempt to reverse the immune suppressive microenvironment and to enhance chemotherapy effectiveness, decrease tumor metagenicity and decrease IL-1-induced fatigue, metastatic breast cancer (MBC) patients will be treated with chemotherapy plus anakinra. This is a pilot safety, single arm, open label trial. The objective is to determine the safety of anakinra plus the physician's chemotherapy choice (TPC) of nab paclitaxel, capecitabine, eribulin, or vinorelbine in patients with MBC and to define an anakinra-induced anti-IL-1 whole blood transcriptional profile.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male patients ≥18 years of age.
- •Histologically confirmed invasive breast cancer, locally unresectable or metastatic.
- •No more than 4 prior chemotherapy regimens for metastatic disease.
- •Patients currently being treated with nab paclitaxel, capecitabine,eribulin, or vinorelbine who have had a CR, PR, or SD and who have developed Grade 2, 3, or 4 fatigue on the chemotherapy are eligible for the study. It should be anticipated that these patients will continue to be treated on the same chemotherapy agent for at least 3 more months beyond the time of enrollment.
- •Prior hormonal therapy in the adjuvant or metastatic setting is permitted.
- •HER2-negative breast cancer. If HER2-, it is defined as follows:
- •FISH-negative (FISH ratio <2.0), or
- •IHC 0-1+, or
- •IHC 2+ AND FISH-negative (FISH ratio<2.0)
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
- •Adequate hematologic function, defined by:
- •Absolute neutrophil count (ANC) >1500/mm^3
- •Platelet count ≥100,000/mm^3
- •Hemoglobin >8 g/dL
- •Adequate liver function, defined by:
- •AST and ALT ≤2.5 x the upper limit of normal (ULN) or ≤5 x ULN in presence of liver metastases
- •Total bilirubin ≤1.5 x ULN
- •Adequate renal function, defined by:
- •a. Serum creatinine ≤1.5 x ULN or calculated creatinine clearance of ≥40 ml/min
- •Measurable or nonmeasurable disease by RECIST v1.1 criteria
- •Life expectancy ≥24 weeks
- •Adequate recovery from recent surgery
- •Major surgical procedure >28 days from study entry
- •Minor surgical procedure >7 days from study entry (Portacath placement accepted - patients can start treatment <7 days after portacath placement.)
- •Patients with previous history of invasive cancers (including breast cancer) are eligible if definitive treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease.
- •Patient must be accessible for treatment and follow-up.
- •All patients must be able to understand the investigational nature of the study and give written informed consent prior to study entry
排除标准
- •Patients with active or untreated brain metastases or meningeal metastases are ineligible. Patients who have had brain metastases resected, or have received brain radiation therapy >4 weeks prior to study entry are eligible if they meet all of the following criteria: 1) patient has been off dexamethasone for >2 weeks; 2) no known progression of brain metastasis.
- •Previous radiotherapy for metastatic disease completed <2 weeks prior to study treatment initiation.
- •Women who are pregnant or lactating. All patients with reproductive potential must agree to use effective contraception from time of study entry until at least 3 months after the last administration of study drug.
- •Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation such as: -
- •severe impaired lung functions as defined as spirometry and DLCO that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air
- •uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
- •liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C).
- •History of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug, or that might affect interpretation of the results of this study, or render the subject at high risk for treatment complications.
- •Patients may not receive any other investigational treatments while participating in this study.
- •Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
- •Concurrent severe, uncontrolled infection or intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
研究组 & 干预措施
Anakinra plus Standard of Care
Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
干预措施: Anakinra plus Standard of Care (Drug)
结局指标
主要结局
Safety - Adverse Events in participants
时间窗: up to 7 months
Patients will receive anakinra plus the physicians chemotherapy choice of nab paclitaxel, or capecitabine, or eribulin, or vinorelbine for metastatic breast cancer. Adverse events will be recorded throughout the trial, and regardless of the severity will be followed up by investigator until resolution is satisfactory. All adverse events and toxicities will be recorded and assessed for 30 days following the last dose of anakinra at a maximum of 6 months. Grading will be done using Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
次要结局
- To determine investigator-assessed objective response rate, clinical benefit rate, progression-free survival, and rates of chemotherapy or cancer-related anemia (HgB<10), and an anakinra-induced anti-IL-1 blood transcriptional signatures(upto 7 months)